Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000644386 | SCV000766079 | benign | Tuberous sclerosis 2 | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001024065 | SCV001186019 | benign | Hereditary cancer-predisposing syndrome | 2021-12-02 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Illumina Laboratory Services, |
RCV001119439 | SCV001277838 | likely benign | Tuberous sclerosis syndrome | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
Genome- |
RCV000644386 | SCV002040300 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000644386 | SCV002097690 | uncertain significance | Tuberous sclerosis 2 | 2020-06-12 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004533370 | SCV004116256 | uncertain significance | TSC2-related disorder | 2023-06-20 | criteria provided, single submitter | clinical testing | The TSC2 c.5413G>A variant is predicted to result in the amino acid substitution p.Glu1805Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.059% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-2138600-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Myriad Genetics, |
RCV000644386 | SCV005406231 | likely benign | Tuberous sclerosis 2 | 2024-08-27 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |